Breaking News
Get 45% Off 0
📈 Q1 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

Incannex Healthcare Ltd ADR (IXHL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Incannex Healthcare ADR's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.581 -0.044    -7.04%
26/04 - Closed. Currency in USD
After Hours
0.580
-0.001
-0.172%
5:00:32 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 14,978
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.580 - 0.630
Incannex Healthcare ADR 0.581 -0.044 -7.04%

Incannex Healthcare ADR Company Profile

 
Explore the Incannex Healthcare ADR company profile for core details about Incannex Healthcare ADR, assess Incannex Healthcare ADR company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryPharmaceuticals
SectorHealthcare
Employees

9

Equity Type

ADR

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Contact Information

Address 8 Century Circuit Suite 105
Norwest Sydney, 2153
Australia
Phone 61 4 0984 0786
Fax -

Top Executives

Name Age Since Title
Joel Bradley Latham 35 2023 President, CEO & Executive Director
Peter Widdows 58 2023 Independent Non-Executive Director
Troy Robert Valentine 50 2023 Non-Executive Chairman
Paul Liknaitzky - 2020 Member of Medical Advisory Board
Mark Bleackley - - Chief Scientific Officer, Head of Programs & Member of the Advisory Board
George E. Anastassov 61 2023 Independent Non-Executive Director & Member of Advisory Board
Robert Bruce Clark 64 2023 Independent Non-Executive Director
Lekhram Changoer 57 2023 CTO & Member of Advisory Board
Alison Wimms - 2025 Member Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IXHL Comments

Write your thoughts about Incannex Healthcare Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email